

Format for Disclosure of Related Party Transactions (Applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sl. No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction	Details of other related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction as per the audit committee	Date of audit Committee Meeting where the information was approved	Value of transaction during the reporting period	Related parties are due to other party as a result of the transaction		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was completed.					Details of the loans, inter-corporate deposits, advances or investments.		Reason for which the loan will be classified by the ultimate recipient of funds (if any)	Notes		
	Name	PAN	Name	PAN								Relationship of the counterparty with the listed entity or its subsidiary	Opening balance	Closing balance	IF case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments	Name (if not already disclosed)	Interest Rate (%)	Term	Secured/ unsecured	Value of the loan/advance/deposit				
1	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Biologics S.A.	ANCC1070D	Below subsidiary	Purchase of goods or services		34243.00	04		14214.00	0.00	0.00											
2	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Export Limited, U.K.	ZZZ22998Z	Below subsidiary	Purchase of goods or services		53171.00	04		53171.00	0.00	0.00											
3	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Pharma India Pvt. Ltd.	AMN13204Z	Below subsidiary	Purchase of goods or services		3699.00	04		2699.00	0.00	0.00											
4	GlaxoSmithKline Pharmaceuticals Limited		GSK Trading Services Limited	ZZZ22998Z	Below subsidiary	Purchase of goods or services		204.00	04		204.00	0.00	0.00											
5	GlaxoSmithKline Pharmaceuticals Limited		BMSB Swayer Limited	AMN13204Z	Subsidiary	Sale of goods or services		162.00	04		162.00	0.00	0.00											
6	GlaxoSmithKline Pharmaceuticals Limited		GSK India Vendor Services Private Limited	AMN13204Z	Below subsidiary	Sale of goods or services		400.00	04		400.00	0.00	0.00											
7	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Research & Development Ltd, U.K.	ANCC1070D	Below subsidiary	Sale of goods or services		50.00	04		50.00	0.00	0.00											
8	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Singapore Inc	ZZZ22998Z	Below subsidiary	Sale of goods or services		18.00	04		18.00	0.00	0.00											
9	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Services International, U.K.	AMN13204Z	Below subsidiary	Sale of goods or services		17.00	04		17.00	0.00	0.00											
10	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Pharma India Pvt. Ltd.	AMN13204Z	Below subsidiary	Sale of goods or services		37.00	04		37.00	0.00	0.00											
11	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Services International, U.K.	AMN13204Z	Below subsidiary	Purchase of goods or services		59.00	04		10.00	0.00	0.00											
12	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline LLC, U.S.A.	AMN13204Z	Below subsidiary	Purchase of goods or services		50.00	04		50.00	0.00	0.00											
13	GlaxoSmithKline Pharmaceuticals Limited		BMSB Swayer Limited	AMN13204Z	Subsidiary	Interest received		14.00	04		14.00	0.00	0.00			Loan	7.75%	0	Unsecured	Nothing charged/loan				
14	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Biologics S.A.	ANCC1070D	Below subsidiary	Any other transaction	Outstanding balance		04		0.00	4751.00	-2375.00											
15	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Export Limited, U.K.	ZZZ22998Z	Below subsidiary	Any other transaction	Outstanding balance		04		0.00	-2839.00	467.00											
16	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Research & Development Ltd, U.K.	AMN13204Z	Below subsidiary	Any other transaction	Outstanding balance		04		0.00	-1347.00	86.00											
17	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Services International, U.K.	AMN13204Z	Below subsidiary	Any other transaction	Outstanding balance		04		0.00	460.00	399.00											
18	GlaxoSmithKline Pharmaceuticals Limited		BMSB Swayer Limited	AMN13204Z	Subsidiary	Any other transaction	Outstanding balance		04		0.00	-36.00	164.00											
19	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Pharma India Pvt. Ltd.	AMN13204Z	Below subsidiary	Any other transaction	Outstanding balance		04		0.00	-367.00	144.00											
20	GlaxoSmithKline Pharmaceuticals Limited		GSK India Vendor Services Private Limited	AMN13204Z	Below subsidiary	Any other transaction	Outstanding balance		04		0.00	165.00	50.00											
21	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Singapore Inc	ZZZ22998Z	Below subsidiary	Any other transaction	Outstanding balance		04		0.00	76.00	50.00											
22	GlaxoSmithKline Pharmaceuticals Limited		GSK Trading Services Limited	ZZZ22998Z	Below subsidiary	Any other transaction	Outstanding balance		04		0.00	0.00	104.00											
23	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline LLC, U.S.A.	AMN13204Z	Below subsidiary	Any other transaction	Outstanding balance		04		0.00	0.00	52.00											
24	GlaxoSmithKline Pharmaceuticals Limited		Dr. Biju Chandy	AMN13204Z	Any management personnel	Remuneration		200.00	04		200.00	0.00	0.00											
25	GlaxoSmithKline Pharmaceuticals Limited		AMY NADARIN	AMN13204Z	Any management personnel	Remuneration		80.00	04		80.00	0.00	0.00											
26	GlaxoSmithKline Pharmaceuticals Limited		Shashan Anilkar	AMN13204Z	Any management personnel	Remuneration		210.00	04		210.00	0.00	0.00											
27	GlaxoSmithKline Pharmaceuticals Limited		BMSB Swayer Limited	AMN13204Z	Subsidiary	Loan		3000.00	04		400.00	400.00	0.00											
28	GlaxoSmithKline Pharmaceuticals Limited		GlaxoSmithKline Egypt SAE	ZZZ22998Z	Below subsidiary	Any other transaction	Outstanding balance		04		0.00	108.00	0.00											
Total value of transaction during the reporting period												33108												

Notes:
 1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions need not be a new related party transaction during the reporting period.
 2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
 3. Listed entities need not be required to provide the disclosures with regard to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed entity.
 4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31.
 5. Companies with financial year ending other than March 31, the six months period shall apply accordingly.
 6. In case of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type.
 7. In case of related party transactions with the same party in the reporting period, for instance, advance transaction with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
 8. In case of multiple related party transactions:
 a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
 b. The value of the related party transaction notified by the audit committee shall be reported in the column "Value of the related party transaction notified by the audit committee".
 c. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
 9. "Net" refers to the net of transactions made for the listed entity. If Transactions such as acceptance of fixed deposits by banks/NBFCs, undertakings with related parties, etc. in the terms uniformly applicable (pertinent to all shareholders) public shall value be reported.